An independent clinical trial, evaluating Medtronic's (Minneapolis) drug-eluting balloon (DEB) technology for the angioplasty treatment of peripheral artery disease (PAD) in the superficial femoral artery, shows promising data for the company's application over conventional, uncoated balloons. (Medical Device Daily) Read More
